Drug Combination Details
| General Information of the Combination (ID: C85406) | |||||
|---|---|---|---|---|---|
| Name | Esculetin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Esculetin enhances TRAIL-induced apoptosis primarily through upregulation of DR5. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral Oncol. 2009 Dec;45(12):1067-72. | |||